Egalet Reports Commercial Launch Of OXAYDO - Quick Facts

(RTTNews) - Egalet Corp. (EGLT), a fully integrated specialty pharmaceutical company, Wednesday announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

OXAYDO is an immediate-release oral formulation of oxycodone Hcl. It is indicated for the management of acute and chronic moderate to severe pain, where the use of an opioid analgesic is appropriate.

Also, OXAYDO is the first and only IR oxycodone designed to discourage abuse via the route of snorting. OXAYDO can be taken without regard to food, the way opioids generally are taken.

OXAYDO is designed to discourage intranasal abuse through its novel, patent protected formulation. The product contains an inactive ingredient that may cause nasal burning if OXAYDO is manipulated.

In a double-blind, crossover study, six times more recreational users reported they would not take OXAYDO again compared to subjects exposed to immediate-release oxycodone.

There is no evidence that OXAYDO has reduced abuse liability compared to immediate-release oxycodone.